Projected Annual Numbers of Nuclear Theranostic Interventions
| Theranostic | No. of patients/y | No. of cycles | Reimbursement (U.S. $) | Revenue (U.S. $/y) | |
| Diagnostic imaging | 68Ga-DOTATATE | 20,000 | 3,000 | 60 (Mil U.S. $/y) | |
| 68Ga-PSMA | 160,000 | 3,000 | 480 (Mil U.S. $/y) | ||
| Total diagnostic | 198,000 | 540 (Mil U.S. $/y) | |||
| Therapeutic | 177Lu-DOTATATE | 7,500 | 30,000 (4 cycles/patient) | 40,000/cycle | 1.2 (Bil U.S. $/y) |
| 177Lu-PSMA | 40,000 | 160,000 (4 cycles/patient) | 20,000/cycle* | 3.2 (Bil U.S. $/y) | |
| Total therapeutic | 47,500 | 190,000 | 4.4 (Bil U.S. $/y) | ||
| Total nuclear theranostics | 4.940 (Bil U.S. $/y) |
↵* Assumed charge/cycle.